| Name | Title | Contact Details |
|---|
MEDJET Assistance is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Simply put, we`re transforming the aging experience so people live longer, healthier lives. By focusing on each person`s abilities and strengths–rather than their limitations–we believe we can impact the healthspan of older adults. Ignited by a passion to inspire older adults to live healthy, meaningful lives, we reach out with our ministries which include: independent and assisted living, rehabilitation, memory support and services including home care, adult day, home-delivered meals, hospice and transportation. As a nonprofit organization guided by Christian compassion, we were founded than 66 years ago as a place for aging Methodist ministers and their spouses to call home. Today, our services are delivered by 1,300 part- and full-time passionate team members throughout the state with a focus on creating healthier and longer lives.
MedAxiom is a Neptune Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ophelia is a digital provider of medication-assisted treatment (MAT) for opioid use disorder (OUD), committed to making evidence-based treatment universally accessible. Its mission is to remove barriers for the 80% of Americans with OUD who are unable to access care and the 50,000+ MAT-licensed clinicians who are unable to treat patients due to a lack of infrastructure, training, and support. At its core is the Ophelia Care Model, a team-based clinical model and software platform developed by leading experts in addiction medicine and psychiatry. Ophelia is licensed to provide care in 36 states and contracted with Medicaid, Medicare, and Commercial insurers covering 85 million American lives.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.